|Bid||6.80 x 300|
|Ask||12.30 x 100|
|Day's Range||8.04 - 8.30|
|52 Week Range||6.27 - 14.63|
|PE Ratio (TTM)||-2.85|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||16.91|
On a per-share basis, the Newton, Massachusetts-based company said it had a loss of 64 cents. The results matched Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...
Q2 2017 Karyopharm Therapeutics Inc Earnings Call
−Pivotal Phase 3 BOSTON Study Underway–. −Updated Phase 1 b/2 STOMP Data Expected by Year End 2017; Top-line Phase 2 b STORM Data Expected by April 2018–. −Phase 2 SEAL Hazard Ratio Expected in September/October ...